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Abstract 
Emphysema, a form of chronic obstructive pulmonary disease (COPD) is a disease of significant 
public health importance that remains a major cause of morbidity and mortality within the US 
population and elsewhere in the industrialized world.  An emerging body of literature appears to 
suggest gender differences in susceptibility to emphysema, with women showing significantly 
less emphysematous changes on high resolution Computed Tomography radiography compared 
to men. A pertinent but yet to be addressed question in the literature however, is whether these 
apparent differences in emphysematous structural lung disease result from differential exposures 
and or lifestyle choices on the one hand, or if on the other hand, these gender differences in CT-
emphysema are related to certain biological mechanisms such as female hormonal influences or 
genetic differences in toxin metabolism.    
 
The present study evaluated differences in CT-emphysema status among 1834 w omen 
with different hormone replacement therapy (HRT) exposure profiles. In an unadjusted 
generalized logistic regression model, current use of HRT was statistically significantly 
associated with a 38% reduction in the risk of moderate to severe CT-emphysema, OR 0.62 
(95% CI=0.39-0.99). After adjusting for the effects of age and smoking dose intensity, current 
HRT-users had a 3 4% reduction in the risk of mild to moderate CT-emphysema compared to 
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never-users. Although this effect is quite sizable, it was marginally statistically insignificant, 
OR=0.66 (95% CI=0.41-1.07). We conclude that current use of hormone replacement therapy 
may be associated with a lower risk of moderate to severe CT-emphysema. 
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1.0  INTRODUCTION AND STATEMENT OF PUBLIC HEALTH SIGNIFICANCE 
Emphysema is a lower respiratory disease defined as an abnormal enlargement of air spaces 
distal to the terminal bronchioles and destruction of alveolar walls1,2. As a distinct clinical entity, 
the onset of emphysema is often insidious but in the long term, manifests as airflow limitation 
that is not fully reversible. Other common clinical manifestations in the course of the natural 
history of the disease include breathlessness, wheezing, and cough, generally progressing over a 
number of years to a disabling impairment of physical and psychological functioning1. Without 
adequate treatment, death from emphysema often results from respiratory and or other systemic 
complications2,3.  
As a disease of public health importance, emphysema which often coexists with chronic 
bronchitis is generally considered in most epidemiological studies under the composite term 
chronic obstructive pulmonary disease (COPD) which includes both diseases3. Tobacco smoking 
is the strongest known risk factor for the diseases, although some studies have implicated genetic 
factors, certain occupations and advancing age in a relatively small minority of cases1,3. As such 
emphysema is considered a largely preventable disease. Because it is a silent disease especially 
at the early stages, the population prevalence of COPD is difficult to estimate3. Most cases 
become apparent only when moderate to severe respiratory problems resulting from the disease 
cause individuals with the condition to seek care. Even when typical clinical symptoms and signs 
are present, the diagnosis of emphysema tends to be difficult, given that until recently, a 
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definitive diagnosis of the disease could only be made through lung biopsies, further worsening 
case ascertainment.    
In spite of the difficulties with case identification, emphysema remains a disease with a 
substantial socio-economic, morbidity and mortality profile. Annual healthcare expenditure on 
emphysema is estimated at more than $2.5 billion in the US alone. This disease also causes or 
contributes to 100,000 d eaths in the U.S. annually4. Emphysema and other COPD forms also 
exert a significant burden of disability, second only to coronary artery disease as the commonest 
cause of disability in the United States. Similarly, data from the third National Health and 
Nutrition Examination Survey (NHANES-III) suggest that about 7% of individuals aged 25-70 
years in the United States currently live with significant airflow limitation. Notably, whereas 
COPD-related mortality has shown a decline among US men, it has increased 150% among 
women over the last twenty years, reflecting likely changes in smoking behavior among the 
female population5.  
1.1 GENDER DIFFERENCES IN CT-EMPHYSEMA RISK 
Recent advancements in computed tomography imaging technology have led to an increasingly 
useful application of Computed Tomography (CT) radiography in emphysema diagnosis, 
shedding more light on structural involvement of lung tissues in emphysema while eliminating 
often-associated lung tissue biopsy complications. An emerging body of pulmonary literature 
appears to show significant differences in the prevalence and patterns of CT-emphysema on the 
basis of gender. In a multichannel helical CT scan evaluation of 396 pa tients enrolled in the 
National Lung Screening Trial (NLST), Dransfeild et al concluded that at all stages of COPD 
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male participants showed more extensive emphysema damage compared to females6, suggesting 
a possible emphysema protective effect for females in the study. Similarly, in a study of 1053 
patients on the National Emphysema Treatment Trial, Martinez at al demonstrated using high 
resolution computed tomography imaging, that women with advanced COPD had significantly 
less emphysematous changes but more extensive airway thickening compared to men, even at 
similar levels of FEV1
7. In a recent report on 688 pa tients on the International COPD Genetics 
Network (ICGN), Camp and his colleagues reported similarly increased emphysema damage 
among male participants in the study, adding that, while female participants tended to have 
increased airway damage relative to emphysema, there were no significant differences in airway 
modification between men and women in the study8. Studies in populations with no spirometric 
evidence of COPD have yielded similar results. In a sample of 957 smokers with no detectable 
airflow obstruction, Sverzellati et al9 found that compared to males, females in the study 
exhibited less extensive emphysematous damage on CT. They added that females were more 
likely to show worsening CT emphysema with age which correlated significantly with FEV1 
values.   
1.2 GENDER DIFFERENCES IN EMPHYSEMA: EVALUATING THE POSSIBLE 
ROLE OF FEMALE REPRODUCTIVE HORMONES 
A growing body of evidence currently points to decreased prevalence and severity of 
emphysematous structural lung damage on C T-scan among women relative to men. Why this 
differential risk exists remains to be substantiated. A number of hypotheses have been put 
forward by commentators7,10 as probable but yet to be tested explanations for these observations. 
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They include the possibility that these findings may in fact be a reflection of the normal 
anatomical differences between adult male and female lungs, or the effect of 
environmental/socio-cultural exposures, genes, hormones or an interaction between any number 
of factors. Given that the differences in emphysematous structural lung damage continue to exist 
on CT even after statistically adjusting for indices of tobacco smoking exposures, age and body 
weight9 it is conceivable that differences in environmental exposures may not be sufficient to 
explain these CT findings.   
 
A line of inquiry focusing on f emale reproductive hormonal exposure and CT-
radiographic outcome may be relevant in the light of current knowledge regarding the role of 
estrogen in lung development, growth, maturation and response to inflammatory stimuli across 
the lifespan. Early in-utero studies in animal models have demonstrated an earlier maturation of 
the lung alveoli in female fetuses relative to male fetuses11,12, possibly explaining findings of 
increased risk of respiratory distress syndrome in male newborns relative to female newborns. 
Subsequent research studies in animal models established that while high androgens levels was 
associated with delayed fetal lung maturation13, administration of estrogens to pregnant females 
accelerated production of surfactants in their fetuses leading to earlier fetal lung alveolar cell 
maturation, irrespective of the gender of those fetuses14,15. Trotter et al further demonstrated the 
in-utero effect of estrogen on lung development, when they showed that prenatal deprivation of 
estrogen led to impairment of alveolar development in newborn piglets16.  
Estrogen has also been shown to play a role in the observed gender differences in 
alveolar cell size and numbers in pubescent rats. Pubescent female rat lungs have smaller and 
more numerous lung alveoli – ideal for gaseous exchange - compared to age-matched male rats. 
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Massaro et al demonstrated that rats ovariectomized on the 21st day of life had larger - and less 
efficient - alveoli as well as smaller alveolar surface areas after 5-6 weeks compared to sham-
ovariectomized rats17. They also showed that estrogen was required in the maintenance of 
alveolar cells and more importantly, that the administration of exogenous estrogen induced 
alveolar cell regeneration in ovariectomized mice following alveolar cell loss18,19. 
The role of estrogen in alveolar cell response to inflammation has also been documented. 
Speyer et al have demonstrated the inflammation-suppressing actions of estrogen in rat lung 
models20. More recently, Vegeto and her co-workers have put forward a hypothesis designating 
the estrogen receptor alpha (ERα) subtype a potential target for anti-inflammatory drugs, after 
they demonstrated its role in the reduction of lung inflammatory response to noxious agents21. 
This finding was further buttressed recently by the findings of Chen et al which showed that 
lungs of rat offspring were hypoplastic and structurally deficient when exposed to in-utero 
nitrofen injury, but nonetheless well developed, if their pregnant mothers received exogenous 
estrogen after the initial nitrofen insult22.  
 
Taken together, studies in animal models strongly suggest that exposure to estrogen at 
various life stages may confer beneficial effects expressed as earlier lung development, increased 
alveolar cell numbers, accelerated growth and maturation, protection of alveolar tissues from 
noxious exposures, as well as alveolar cellular regeneration following lethal or near-lethal 
insults. At present, it is not clear if these effects apply to human lungs and alveolar cells. If they 
do, then it may help explain the findings of decreased radiographic emphysema severity in 
females compared to males and the accelerated decline in alveolar integrity with advancing age 
among post-menopausal females noted in some studies9.  
   6 
This present study will therefore aim to understand if exposure to female reproductive 
hormones, specifically, use of hormone replacement therapy has any effect on t he risk of 
emphysema among female participants in a lung cancer screening study.  
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2.0  STUDY POPULATION, EXPOSURE AND OUTCOME VARIABLES  
2.1 STUDY POPULATION 
Participants in this study are females enrolled in the Pittsburgh Lung Screening Study (PLuSS) 
cohort. Conceived and conducted as one of the sub-projects of the University of Pittsburgh’s 
Lung Cancer Specialized Program of Research Excellence (SPORE), the PLuSS is a community-
based lung cancer screening study using low dose multi-detector helical CT. To be eligible, 
participants had to meet the following selection criteria: Age between 50-79 years at the time of 
entry into the study, be a current or former smoker with at least a 25 year history of smoking of 
at least half a pack of cigarettes a day on the average, if quit, has not been quit for more than 10 
years, no hi story of chest CT scans in the previous 12 months, not a participant in another 
ongoing cancer screening study, body weight less than 400 pounds and must have signed an 
informed consent form.  
A total of 3755 individuals who met the above eligibility criteria were recruited into the 
study. Gender distribution in the study was fairly balanced with 1836 women (~49%) and 1919 
men (~51%).  In addition to the multi-detector CT scan, participants also received spirometric 
Pulmonary Function Tests (PFTs), donated biological tissue samples, including saliva, sputum 
and blood, and filled out detailed questionnaires on their smoking behavior, cancer history and 
other factors of interest. Of particular importance to this study, female participants also filled out 
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a reproductive history questionnaire that detailed such variables as age at menarche, menopause 
status and exogenous hormone use.  Further details of subject demographics, study design and 
methodology have been published elsewhere23,24. Participant follow up in the PLuSS is currently 
ongoing.  
2.2 EXPOSURE  
2.2.1 MEASURES OF EXPOSURE 
Exposure to hormone replacement therapy is the major exposure variable in this study. Specific 
measures of exposure include the following: HRT-use classed as (1) never-use, (2) ever-use and 
(3) current use. Other measures of exposure include HRT use duration (among ever and never 
users) and duration of current use class (less than 1 year, 2-3 years, 4-5 years, 6-9 years and 
greater than 10 years).  
2.2.2 DETERMINANTS OF EXPOSURE - HORMONE REPLACEMENT THERAPY 
Of the 1836 women in the PLuSS, two participants with missing information on hor mone 
replacement therapy (HRT) status were excluded leaving a total of 1834 women eligible for 
analysis. Of this number of women with HRT-use history, 611 (33.3%) self-identified as never-
users, 755 (41.1%) self-identified as former-users, while 468 (25.5%) reported current use.  In 
order to gain a better understanding of the distribution of participants in these classes of HRT-
use, we used a frequency procedure and chi-square statistics to evaluate the relationship between 
   9 
certain important predictor variables and HRT status. These include age at completion of the 
baseline questionnaire, smoking intensity (cigarettes per day) and physician diagnosed 
emphysema (MD-Emphysema).  
 
The entire study population distributed according to age in the following manner: 30.5% 
50-54 years, 28.6% 55-59 years, 20.4% 60-64 years and 20.5% 65 years and older.  There was a 
significant relationship between age and HRT status (p<0.0001). The never-HRT category 
contained a relatively higher proportion (38.8%) of women in the youngest (50-54 years) age 
group and relatively lower proportions of women (21.9%, 15.4% and 23.9%) in the intermediate 
(55-59 and 60-64 years) and older (65 years and older) age groups respectively. The current user 
group contained a relatively higher proportion of women, 31.8% and 30.3% in the 50-54 years 
and 55-59 years age groups categories respectively, with lower proportions, 22.2% and 15.6% 
were in the 60-64 years and 65 years and older age groups respectively. This may be due to the 
fact that while a relatively larger proportion of younger women may not have reached 
menopause (and therefore have no menopausal symptoms requiring treatment), older women are 
more likely to have transitioned through menopause and thus not likely to require current 
hormonal treatment.  
 
A significant relationship was also demonstrated between age group category and 
duration of use among ever-HRT users (p<0.0001). Among ever HRT users of one year duration 
or less, the proportion of women in the younger (50-54) age group was 39.7% which is higher 
than the proportion of 50-54 year-old women (10.2%) in the 10+ year ever HRT use category. 
Also, only 13.1% of ever-users of ≤1 year duration fell in the oldest (65+ year) age group, while 
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a higher proportion, 30.5% of ever users greater than or equal to 10 years were women in the 
oldest (65 years and older) age group category. This association may be explained by the fact 
that older women are more likely to have had the onset of menopause for much longer than 
younger women. A similar distribution pattern is shown in the current-user table. The current-
user less than one year category, was entirely composed of women 50-54 years (69%) and 55-59 
years (31%), while the current users of ten years or more were distributed in this manner; 50-54 
year old group 13.7%, 55-59 year old group 22.6%, 60-64 year old group (36.8%) and 65 years 
and older 26.9%. (Please see Table 1.)       
 
There was no relationship demonstrated between either smoking intensity or physician-
diagnosed emphysema and HRT status (p=0.88 and 0.07 respectively). However, it is worthy of 
note that whereas the prevalence of physician diagnosed emphysema is 6.6% among all current 
HRT users, the prevalence was about 50% higher among never users and former users (9.3% and 
10.5% respectively). This observation may suggest an inverse association between current HRT 
use and physician diagnosed emphysema but this relationship may possibly be confounded by a 
number of other variables.    
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Table 1: Association between selected characteristics and hormone replacement therapy history 
Characteristic ALL Never Former Current p-value <=1 2-3 4-5 6-9 10+ p-value <=1 2-3 4-5 6-9 10+ p-value
ALL N 1834 611 755 468 237 195 157 222 410 29 71 55 101 212
AgeGroup (years) <0.0001 <0.0001 <0.0001
% 30.5 38.8 22.9 31.8 39.7 39.5 31.8 26.1 10.2 69.0 63.4 43.6 30.7 13.7
% 28.6 21.9 33.0 30.3 34.2 33.3 38.2 42.8 22.0 31.0 22.5 45.5 43.6 22.6
% 20.4 15.4 23.3 22.2 13.1 12.8 17.8 18.9 37.3 0.0 9.9 5.5 15.8 36.8
% 20.5 23.9 20.8 15.6 13.1 14.4 12.1 12.2 30.5 0.0 4.2 5.5 9.9 26.9
Cigarettes per day 0.8787 0.7516 0.8288
% 3.7 4.6 2.9 3.8 3.0 3.1 1.3 3.6 4.1 3.4 4.2 0.0 3.0 5.2
% 33.6 32.6 33.8 34.6 34.2 36.4 33.1 30.6 35.1 37.9 38.0 36.4 28.7 35.4
% 43.8 43.5 44.1 43.6 42.6 45.1 48.4 45.9 41.5 44.8 46.5 45.5 47.5 40.1
% 13.2 13.6 13.6 12.0 13.5 12.8 10.2 14.4 12.9 6.9 9.9 10.9 14.9 12.3
% 5.7 5.7 5.6 6.0 6.8 2.6 7.0 5.4 6.3 6.9 1.4 7.3 5.9 7.1
MD-Emphysema 0.0742 0.5811 0.7808
% 90.9 90.7 89.5 93.4 89.9 89.2 92.4 93.2 90.7 93.1 93.0 96.4 91.1 93.9
% 9.1 9.3 10.5 6.6 10.1 10.8 7.6 6.8 9.3 6.9 7.0 3.6 8.9 6.1
Current user, by duration of use in yearsEver users, by duration of use in years
50-54
55-59
10 to 19
20 to 29
30 to 39
40 or more
no
60-64
65+
HRT status
yes
1 to 9
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2.3 OUTCOME 
2.3.1 MEASURES OF OUTCOME 
Measurement of CT-emphysema outcomes was based on the standards developed by the 
National Emphysema Treatment Trial criteria. This is essentially a five-level semi-quantitative 
CT image scoring system graded as (1) no, (2) trace, (3) mild, (4) moderate, and (5) severe 
emphysema. The trace, mild, moderate and severe categories roughly correspond to emphysema 
affecting less than 10, 1 0–25, 25–50%, and greater than 50% of the lung, respectively. This 
grading system was applied in the scoring of participants’ CT scans by three readers including 
two radiologists and a pulmonologist.  
2.3.2 DETERMINANTS OF CT-EMPHYSEMA SCORE – DEMOGRAPHIC 
VARIABLES 
Of the 1834 participants with HRT use information, 66 had no baseline CT-Emphysema score 
and were excluded, leaving 1768 women eligible for the final analysis. Owing to the sparse data 
in the moderate and severe CT-Emphysema score groups, both groups were merged to form the 
“greater than mild” group. Of the 1768 w omen not missing CT-emphysema scores, 1070 
(60.5%) had no emphysema on their baseline CT scan, while 306 (17.3%), 233 (13.2%) and 159 
(8.9%) had trace, mild and greater than mild emphysema on their CT scan images. The 
relationship between and CT-Emphysema scores and various demographic variables including 
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age, educational status, BMI and history of physician diagnosed emphysema were evaluated 
using simple chi-square statistic.  
 
The analysis (See Table 2 be low) demonstrated that increasing age was significantly 
associated with CT-emphysema (p<0.0001). The entire 1768 w omen in the study were age 
distributed as follows: 30% 50-54 years, 28.5% 55-59 years, 20.6% 60-64 years and 20.9% 65 
years and over. Among women with no CT-emphysema, a relatively higher proportion (32.6%) 
was aged 50-54 years whereas lower proportions (30.9%, 18.8% and 17.7%) were in the 55-59 
years, 60-64 years and 65 years and over age groups. In the moderate to severe emphysema, 
group, only 18.2% fell in the 50-54 age group while 36.5% fell in the the oldest (65 years and 
over) age group. This suggests that increasing age was associated with the presence of CT-
emphysema. 
 
Body mass index (BMI) also showed a strong association with CT-emphysema 
(p<0.0001). Among women with moderate to severe emphysema, a higher proportion, 57.6% 
belonged to the lower BMI (16-24.99) category with lower proportions 31.0% and 11.4%, 
belonging to the overweight and obese categories respectively. This contrasts with the no-
emphysema group where only 24.6% belonged to the 1ower BMI category while higher 
proportions, 36.3% and 39.0 belonged to the overweight and obese categories respectively.  
A statistically significant relationship was also established between CT-emphysema and 
physician diagnosed emphysema (p<0.0001). It is important to note that the prevalence of 
physician diagnosed emphysema was six-fold more common (31.4%) among the mild to 
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moderate CT-emphysema group compared to the no CT-emphysema. There was no association 
between educational attainment and CT-emphysema (p=0.15). 
 
Table 2: Association between selected risk factors and CT emphysema 
    (missing observations shown in parenthesis) 
Characteristic ALL None Trace Mild >Mild p-value
ALL N 1768 1070 306 233 159
Age <.0001
% 30.0 32.6 32.7 22.3 18.2
% 28.5 30.9 27.1 24.9 19.5
% 20.6 18.8 21.9 24.0 25.8
% 20.9 17.7 18.3 28.8 36.5
Education (1) (1) 0.15
% 27.4 26.0 27.1 30.5 32.7
% 41.9 42.4 38.6 44.2 41.5
% 30.7 31.6 34.3 25.3 25.8
BMI (kg/m2) (4) (2) (1) (1) <.0001
% 31.9 24.6 38.0 39.5 57.6
% 36.6 36.3 35.7 42.9 31.0
% 31.5 39.0 26.2 17.6 11.4
History of emphysema <.0001
% 90.8 94.8 92.5 85.8 68.6
% 9.2 5.2 7.5 14.2 31.4
High School or Less
Post High School
College or Postgraduate
16 - 24.99
25-29.99
30 or Greater 
50-54 years
55-59 years
60-64 years
65 years and above
CT Emphysema
no
yes  
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2.3.3 DETERMINANTS OF CT-EMPHYSEMA SCORE - SMOKING RELATED 
FACTORS 
As shown in the table below, most measures of tobacco smoking including average number of 
cigarettes smoked per day, number of pack years smoked, smoking duration, and type of 
cigarette smoked all showed strong statistical relationships with CT emphysema (p<.0001). 
Current smoking was also associated with CT-emphysema class (p=0.0072). An interesting 
observation is that the prevalence of quitting (current smoking = no) appears similar for women 
with no CT-emphysema (39.6%) and those with moderate to severe emphysema (39.0%). It is 
possible that the higher than expected prevalence of quitting among those with moderate to 
severe emphysema may be explained by possible increased severity of emphysema symptoms 
among these women that may have prompted them to quit. Age at onset of regular tobacco 
smoking showed no relationship with CT-emphysema class (0.3884). 
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Table 3: Association between smoking-related factors and CT-Emphysema 
 
Characteristic ALL None Trace Mild >Mild p-value
ALL N 1768 1070 306 233 159
Current smoking status 0.0072
% 63.1 60.4 69.9 67.8 61.0
% 36.9 39.6 30.1 32.2 39.0
Cigarettes per day  <.0001
% 3.6 4.8 2.3 2.1 0.6
% 33.3 36.2 33.3 28.8 20.8
% 44.0 42.3 44.8 45.5 51.6
% 13.3 11.0 14.1 17.6 20.8
% 5.8 5.7 5.6 6.0 6.3
Pack-years <.0001
% 22.0 26.6 21.9 12.0 5.7
% 20.1 21.1 19.3 19.3 15.7
% 19.9 19.6 19.3 20.6 21.4
% 16.7 15.2 16.3 20.2 22.0
% 21.4 17.4 23.2 27.9 41.5
Smoking duration (yrs) <.0001
% 60.8 65.4 62.4 49.4 43.4
% 39.2 34.6 37.6 50.6 56.6
Type of cigarette smoked  <.0001
% 92.0 94.0 90.2 90.6 83.6
% 2.8 1.6 5.6 3.0 5.0
% 5.3 4.4 4.2 6.4 11.3
Age started smoking 0.3884
% 23.0 21.4 24.8 26.2 25.8
% 58.7 59.8 55.6 59.2 56.0
% 18.3 18.8 19.6 14.6 18.2
40 or more cigarettes/day
Yes
                                                              CT Emphysema           
No
1 to 9 cigarettes/day
10 to 19 cigarettes/day
20 to 29 cigarettes/day
30 to 39 cigarettes/day
Less than 30
30-39
40-49
50-59
60 or more
Less than 16 years
16-20 years
21 years or over
Less than 40 years
40 years or more
Filter cigarette
Non-filter cigarette
Both about equally
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2.3.4 DETERMINANTS OF CT-EMPHYSEMA SCORE – FACTORS RELATED TO 
REPRODUCTIVE HORMONE  
As shown in the table below, most female reproductive hormone related-factors including age at 
onset of menarche, menopausal status, age at menopause, age at first pregnancy and number of 
pregnancies all showed no statistical relationship with CT-emphysema. However, use of oral 
contraceptive pills (OCP) showed a weak statistical relationship with CT-emphysema (p=0.053) 
while age at onset of oral contraceptive use among ever OCP users showed a strong relationship 
with CT-emphysema (p<.0001). Among 1240 participants with non-missing history of OCP use, 
the proportion of those who reported starting OCP use at age less than 20 years was 20.5%, 
67.9% reported starting OCP use at age 22-29 years while 11.6% reported starting OCP use aged 
30 years or more. Among women with moderate to severe CT-emphysema in the study, a lower 
proportion (10.2%) started OCP use at age less than 20 years, while a higher proportion started 
OCP use at thirty years or later (27.8%). This suggests that earlier age at onset of OCP use may 
be associated with a reduced risk of moderate to severe CT-emphysema, although this 
relationship may be confounded by other variables including age.  
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Table 4: Association between reproductive-related factors and CT emphysema  
(missing observations shown in parenthesis)  
Characteristic ALL None Trace Mild >Mild p-value
ALL N 1768 1070 306 233 159
Age at menarche (2) (1) (1) 0.0607
% 22.7 23.7 18.7 24.6 20.8
% 54.6 53.4 59.7 55.6 51.6
% 18.4 19.5 16.7 13.8 20.8
% 4.3 3.4 4.9 6.0 6.9
Menopausal 0.0904
% 94.9 94.0 95.1 96.6 98.1
% 5.1 6.0 4.9 3.4 1.9
Age at menopause* (8) (4) (2) (1) (1) 0.1963
% 20.2 20.4 20.1 19.6 20.6
% 18.0 16.3 19.7 21.4 20.6
% 29.8 29.2 30.8 31.3 29.0
% 28.0 30.8 24.6 21.9 25.2
% 4.0 3.3 4.8 5.8 4.5
Ever pregnant 0.3569
% 14.0 14.4 16.0 11.6 11.3
% 86.0 85.6 84.0 88.4 88.7
Age first pregnant** (2) (1) (1) 0.7280
% 28.1 27.7 27.3 27.3 32.6
% 43.1 42.9 45.7 41.0 43.3
% 20.7 21.8 18.0 21.5 17.0
% 5.9 5.2 7.0 6.8 6.4
% 2.2 2.3 2.0 3.4 0.7
Number of pregnancies (2) (1) (1) 0.2664
% 14.0 14.4 16.1 11.6 11.3
% 34.9 36.6 30.8 33.6 33.3
% 34.8 34.6 34.8 34.9 36.5
% 16.2 14.4 18.4 19.8 18.9
OCP Use (4) (1) (1) (1) (1) 0.053
% 29.9 28.4 27.5 38.4 32.3
% 16.8 16.7 21.0 12.1 17.1
% 39.2 40.8 37.7 34.1 38.6
% 14.1 14.1 13.8 15.5 12.0
Age OCP use started*** <.0001
% 18.9 20.5 22.0 12.2 10.2
% 67.7 67.9 67.9 70.3 62.0
% 13.5 11.6 10.1 17.6 27.8
14-15 years
Less than 12 years
12-13 years
                                                              CT Emphysema           
1 to 2
3 to 4
Yes
No
Less than 40 years
40-44 years
45-49 years
50-54 years
55 years or older
Less than 19 years
Yes
20-24 years
25-29 years
30-34 years
35-44 years
0
20-29 years
30 years or more
16 years or older
No
5 or more
None
One year or less
2-9 years
10 years or more
Less than 20 years
 
*Analysis restricted to menopausal participants 
**Analysis restricted to ever-pregnant participants 
***Analysis restricted to ever-OCP use 
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3.0  HORMONE REPLACEMENT THERAPY AND CT-EMPHYSEMA         
In order to understand the relationship between hormone replacement therapy and CT-
emphysema, a frequency procedure with a simple chi-square test was conducted to assess the 
relationship between the two variables. Globally, there was no statistically significant 
relationship between CT-emphysema class and hormone replacement therapy status (p=0.43). As 
earlier stated and shown in the table 5 below, 66 women with no baseline CT were excluded 
from the final analysis. The rest of the study group was distributed according to CT-Emphysema 
status in the following manner:  60.5% no CT-emphysema, 17.3% trace, 13.2% mild and 9.0% 
moderate to severe CT-emphysema. Of note, the prevalence of moderate to severe CT-
emphysema was about 60% higher (10.2%) among never HRT-users compared to the prevalence 
among current HRT-users (6.4%).  
  There were no statistically significant relationships between CT-emphysema and duration 
of use among ever-users (p=0.38) or current users (p=0.28) respectively.   
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Table 5: Association between measures of hormone replacement therapy exposure and CT emphysema  
(missing observations shown in parenthesis) 
Characteristic ALL Never Former Current p-value <=1 2-3 4-5 6-9 10+ p-value <=1 2-3 4-5 6-9 10+ p-value
ALL N 1834 611 755 468 237 195 157 222 410 29 71 55 101 212
CT emphysema (66) (32) (22) (12) 0.43 (11) (5) (4) (6) (8) 0.38 (2) (1) (0) (3) (6) 0.28
% 60.5 60.3 60.6 60.7 64.6 60.5 66.0 55.6 59.2 66.7 60.0 74.5 51.0 61.2
% 17.3 17.8 16.0 18.9 15.0 14.2 19.6 20.4 16.7 18.5 17.1 18.2 25.5 16.5
% 13.2 11.7 13.8 14.0 11.9 16.3 9.8 15.3 14.7 11.1 18.6 3.6 15.3 15.0
% 9.0 10.2 9.7 6.4 8.4 8.9 4.6 8.8 9.5 3.7 4.3 3.6 8.2 7.3
Current user, by duration of use in yearsEver users, by duration of use in yearsHRT status
moderate or severe
none
trace
mild
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4.0  ADJUSTED RELATIONSHIP BETWEEN HORMONE REPLACEMENT 
THERAPY AND CT-EMPHYSEMA  
4.1 LOGISTIC REGRESSION MODEL 
A generalized logistic regression analysis was conducted with CT-emphysema score as the 
outcome variable and HRT use as the main predictor variable. Age and tobacco smoking dose 
intensity were sequentially added to the model, thus controlling for these possible confounders. 
Each unadjusted odds ratios (OR1) compares the odds of CT-emphysema among former HRT 
users and current HRT users respectively to never users for each of the three CT-emphysema 
classes (trace, mild, greater than mild). These odds ratios were then sequentially adjusted for age 
(OR2) and smoking dose intensity (OR3). All statistical analyses were conducted using SAS 
(version 9.2, Cary North Carolina).  
4.2 RESULTS 
As shown in Table 6 below, there is no global statistically significant relationship detected 
between CT-emphysema and hormone replacement therapy status (p=0.27), although a closer 
review of the results appear very instructive. Compared to never-users, the unadjusted odds ratio 
(and 95% confidence interval) values for trace, mild and moderate to severe CT-emphysema 
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among former users of HRT, were as follows: 0.89 (0.66-1.20); 1.17 (0.83-1.64) and 0.95 (0.65-
1.37) respectively. Sequential adjustments for age and smoking dose intensity did not 
significantly change these values (p=0.39 and 0.41 respectively).  (See table 6).  
 
There was a significant relationship between current HRT use and the unadjusted odds of 
mild to moderate CT-emphysema, but there was no association between current use and the odds 
of trace or mild CT-emphysema. For current HRT-users, the unadjusted odds ratio for moderate 
to severe CT-emphysema was about 40% lower compared to never users, OR=0.62 
(95%CI=0.39-0.99). After adjusting for age and smoking intensity, the odds of moderate to 
severe CT-emphysema among current HRT-users was 34% lower among current HRT-users 
compared to non-users OR=0.66 (95%CI=0.41-1.07).  
 
The unadjusted odds ratio (and 95% confidence limits) for trace and mild CT-emphysema 
for current users compared to never users were 1.05 ( 95% CI=0.76-1.46) and 1.19 (95% 
CI=0.89-1.73) respectively. After adjustments for age and smoking intensity, the odds ratio 
showed very little changes, OR trace CT-emphysema=1.06 (95% CI=0.76-1.47); OR mild CT-
emphysema=1.23 (95% CI=0.89-1.80).   
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Table 6: Association between hormone replacement therapy history and CT emphysema 
unadjusted (OR1, p-value=0.27), adjusted for age (OR2, p-value=0.39), and adjusted        
for age and cigarette dose intensity (OR3, p-value=0.41). 
HRT None Trace Mild >Mild
Never N 349 103 68 59
Former N 444 117 101 71
OR1 0.89 1.17 0.95
0.66-1.20 0.83-1.64 0.65-1.37
OR2 0.89 1.13 0.91
0.66-1.21 0.80-1.59 0.62-1.34
OR3 0.89 1.13 0.92
0.66-1.21 0.80-1.60 0.63-1.35
Current N 277 86 64 29
OR1 1.05 1.19 0.62
0.76-1.46 0.81-1.73 0.39-0.99
OR2 1.05 1.21 0.65
0.76-1.46 0.83-1.78 0.40-1.05
OR3 1.06 1.23 0.66
0.76-1.47 0.84-1.80 0.41-1.0795% CI
CT emphysema
95% CI
95% CI
95% CI
95% CI
95% CI
 
 
 
Legend: OR1 – crude odds ratio, OR2 – age-adjusted odds ratio, OR3 – age- and cigarette dose intensity-
adjusted odds ratio, CI – confidence interval 
Notes:  A ll odds ratio referenced to HRT never users without CT emphysema. Odds ratios 
adjusted by means of generalized logit models with age modeled as a four level categorical variable (50-
54, 55-59, 60-64, and 65+ years) and cigarette dose intensity modeled as an  ordinal variable (integer 
index assigned to cigarettes/day expressed as five ordered categories, 1-9, 10-19, 20-29, 30-39, 40+ 
cigarettes/day).  
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5.0  DISCUSSION AND LIMITATIONS 
5.1 DISCUSSION 
In this analysis, no global statistically significant relationship was established between hormone 
replacement therapy (HRT) use and CT-emphysema. There are two potentially valid conclusions 
to be drawn from the results of this analysis. The first, possibly demonstrated by the global 
statistical significance values above is that no r elationship exists between HRT use and CT-
emphysema.  
 
Alternatively, the study group may have been too small to detect a statistically significant 
inverse association between current HRT use and greater than mild CT-emphysema, a 
relationship suggested by the observed lower age- and smoking intensity-adjusted odds of greater 
than mild emphysema (vs. no emphysema, OR 0.66, 95% CI 0.41-1.07) in current HRT vs. never 
HRT users (Table 6). First, as shown in table 6, current use of HRT was associated with a large 
(38%) and statistically significant reduction in the unadjusted risk of moderate to severe 
emphysema. This large effect size persisted even after adjustments for age and smoking 
intensity, although statistically, the relationship became marginally insignificant. Given that the 
current HRT-users with moderate to severe CT-emphysema represent a very small proportion of 
the total sample size; 29 of the 1768 women (1.64%), it is possible that we did not have enough 
 25 
power to detect a s tatistical significance, even in the presence of a v ery large effect size (35-
38%).  Finally, it is important to note that the large risk reduction demonstrated among current 
HRT-users may be clinically or radiographically significant and agrees with current knowledge 
regarding the effects of estrogen on alveolar cell development, growth, and regeneration in 
animal models12,16,20-22.  
5.2 LIMITATIONS 
This study is a cross sectional study with some noteworthy limitations. First, the 
aphorism “association does not imply causation” rings true, given that a proof of causation (or 
the lack of it) as it applies to HRT use and CT-emphysema cannot be established by this study 
alone. Further research in this area is therefore encouraged 
The second is that the exposure variables including age, indices of tobacco smoking 
behavior and reproductive history including HRT use exposure information are accurate to the 
extent that they are self-reports. It is possible that case classification or sub-classification may 
have been affected by the degree of accuracy of the provided self report information.  
Third, determination of CT-emphysema outcome status was made using a semi-
quantitative procedure. Given the element of subjectivity introduced in the CT-reading process, it 
is possible that discrepancies in CT reading and subsequent case allocation may have affected the 
classification of CT-emphysema. This uncertainty may be eliminated in future studies by using 
machines with fully quantitative and standardized CT-emphysema assessment system based on 
percent low attenuation areas (% LAA) scores.  
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Fourth, it is possible that our findings in this study may have been confounded by other 
variables not accounted for in the logistic regression model. These include other reproductive 
hormone variables, particularly use and duration of use of oral contraceptive pills (OCPs), as 
well as body mass index (BMI) which showed strong statistical relationships with CT-
emphysema in univariate models (see tables 2 and 4). Future studies will explore the effects of 
these variables on CT-emphysema outcome. 
 In the future, further studies with larger sample sizes may help to firmly establish or 
disprove an association between HRT use and CT-emphysema.  
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